Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds

Exclusion Criteria

• •1. Hypersensitivity to silver or fresh frozen plasma.
• •2. Active infection or history of radiation to the donor site.
• •3. Insensate at the donor site.
• •4. Elevated INR\>3.0.
• •5. The subject was previously entered into this study or had participated in any study drug or medical device study within 30 days of screening.
• •6. Currently on a treatment regimen or medications which in the opinion of the investigator are known to interfere with wound healing (for example: cancer chemotherapy or equivalent immunosuppressants, systemic steroids \> 10 days of treatment, cytostatic drugs, COX-2 inhibitors, or radiation therapy).
• •7. Excessive lymphedema that in the opinion of the investigator will interfere with wound healing.
• •8. A cognitive, physical, or psychological condition interfering with subject's ability to comply with the treatment regimen.
• •9. Subject is on dialysis.
• •10. Patients who are pregnant, breast feeding, or unwilling to practice contraceptive methods during participation in the study, if applicable. Effective methods of contraception include:
• •i. oral, injectable, or implanted hormonal contraceptives ii. intrauterine device or system, iii. barrier method with spermicide, or iv. bilateral tubal occlusion.
• •11. Patients with uncontrolled anemia (Hgb\<10 g/dL in women; \<12 g/dL in men) at Screening.
• •12. Severe malnutrition (serum albumin ≤2.0 with a normal CRP).